TrialCompass™ TCL
Back to trials
RecruitingPriority 4 · Lower priorityNCT07270861

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

ClinicalTrials.gov

Plain-language summary

This trial is testing Observational for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Observational (OTHER): Observational

  • Observational

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

NCT07270861

Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing Observational for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

What's being tested

Observational (OTHER): Observational

Drugs / treatments: Observational

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 3000 patients

Primary endpoint: Distribution of PTCL Histological Subtypes according to WHO 2016 Classification; Overall Survival (OS); Progression-Free Survival (PFS)

Ages: 18 Years to —

Start date: 2025-11-15 | Est. completion: 2035-12-31

Locations

0 US sites · 1 total

Contact

Rong Tao, MD | hkutao@hotmail.com | 008621-64175590

Sponsor: Fudan University (OTHER)

Tags

All T-cell lymphomas · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07270861

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.